ArticleInternational urology and nephrology2025
"Exploring benefits of L-carnitine in hemodialysis: promising findings await clinical application".
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
L-carnitine, a crucial component in the metabolism of fatty acids, has shown promise as a treatment for malnutrition and cardiovascular disease in hemodialysis patients. The 2025 meta-analysis by Nabi et al., which documented a statistically significant improvement in left-ventricular ejection fraction (LVEF) after L-carnitine supplementation, is the focus of this letter's evaluation of previous data. Although there has been a noticeable increase in systolic performance, there are still conflicting data on diastolic function and left-ventricular mass index (LVMI). Furthermore, it is becoming more widely acknowledged that L-carnitine deficit contributes to malnutrition in patients on maintenance hemodialysis. This highlights the need for thorough, high-quality clinical trials to confirm the therapeutic efficacy of L-carnitine and evaluate its influence on long-term clinical outcomes.
Indexed as
Identifiers
40281379What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.